1. Efficacy and safety of interferon α-2b spray for herpangina in children: A randomized, controlled trial
- Author
-
Guangmin Nong, Jianhua Hao, Shao-Ning Wang, Jikui Deng, Ru-Ping Luo, Ying-Zi Ye, Hui Yu, Zhi Yang, Yan Chen, Bi-Quan Chen, Weili Yan, Lu Gan, Ai-Wei Lin, Ya-Lan Dou, Min Lei, Li Zhou, Yuan-Yuan Long, and Yi-Nan Liao
- Subjects
Male ,0301 basic medicine ,Microbiology (medical) ,China ,Herpangina ,medicine.medical_specialty ,Fever ,030106 microbiology ,Interferon α-2b ,Infectious and parasitic diseases ,RC109-216 ,Interferon alpha-2 ,Antiviral Agents ,Body Temperature ,law.invention ,Clinical study ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Primary outcome ,Double-Blind Method ,Randomized controlled trial ,Recombinant human interferon α-2b spray ,law ,Interferon ,Internal medicine ,Ribavirin ,medicine ,Humans ,030212 general & internal medicine ,Child ,Adverse effect ,Children ,Oral Ulcer ,business.industry ,Infant ,General Medicine ,medicine.disease ,Infectious Diseases ,chemistry ,Child, Preschool ,Female ,Therapy ,Oral Sprays ,Age of onset ,business ,medicine.drug - Abstract
Objectives: The treatment of acute herpangina is inconsistent. We aim to evaluate the effectiveness and safety of interferon α-2b spray versus Ribavirin for this disease. Methods: A randomized, controlled trial was conducted in eight hospitals in China between 2016 and 2018. 668 patients (1–7 years old) were randomized into an experimental group (treated with Interferon α-2b spray) or control group (received Ribavirin Aerosol). Body temperature returning to normal within 72 h and remaining so for 24 h was the primary outcome; release of oral herpes and adverse events were the secondary outcomes. Results: (1) The average age of onset was 2.5 years old. (2) After 72 h treatment, body temperature of 98.5% patients in experimental group and 94.3% in control group returned to normal and remained so for 24 h (P = 0.004). The differences were greater at 48 h treatment (95.2% vs. 85.9%, P < 0.001) and at 24 h (77.5% vs. 66.5%, P = 0.001). (3) The rate of improved oral herpes in the experimental group was higher than that in control group (46.7% vs.37.1%, P = 0.011). No adverse reaction occurred. Conclusions: Local application of recombinant interferon α-2b spray showed better efficacy for acute herpangina in children. It was safe for use.
- Published
- 2021